Mega Genomics Limited disclosed that it repurchased 110,000 ordinary shares on 24 July 2026 through on-market transactions at HKD 7.08 per share, for a total consideration of HKD 0.78 million. The buy-back represents 0.0491% of the company’s issued share capital (excluding treasury shares) as of 21 July 2026.

Following the transaction, issued shares (excluding treasury shares) fell from 223.84 million to 223.73 million, while treasury shares increased from 458,600 to 568,600. The total number of issued shares remained unchanged at 224.30 million. Treasury shares now account for approximately 0.25% of the company’s outstanding share capital.

The repurchase was executed under the mandate approved on 21 May 2026, which authorises the company to buy back up to 22.43 million shares. Cumulative repurchases under this mandate have reached 568,600 shares, utilising 0.25% of the authorised limit.

In line with Hong Kong listing rules, Mega Genomics is subject to a moratorium on issuing new shares or disposing of treasury shares until 24 August 2026.